Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front Med Chin    2009, Vol. 3 Issue (2) : 181-186     DOI: 10.1007/s11684-009-0025-6
RESEARCH ARTICLE |
Prospective research on the efficacy and safety of oxcarbazepine as monotherapy and add-on therapy for partial epilepsy
Huicong KANG, Xiaoyan LIU, Hu QI, Feng XU, Xiang LI, Yuan WANG, Zhiguang LIU, Suiqiang ZHU()
Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
Download: PDF(110 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract  

The purpose of our research was to evaluate the efficacy, tolerance, and safety of oxcarbazepine (OXC) as monotherapy and add-on therapy for partial epilepsy. We carried out a prospective clinical follow-up trial at the Epilepsy Center of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. Sixty-seven patients with partial epilepsy received OXC therapy. The patients were randomly divided into a monotherapy group and an add-on therapy group. We observed the efficacy and safety in the first three months and the following three months respectively, and compared them with each other. There was a significant difference in the decrease of seizure frequency between the two groups (P = 0.002). There was a significant difference in the percentage of seizure-free between the monotherapy and the add-on therapy groups in the first three months (P = 0.02), and there were also statistical differences in the 50% response rate (P = 0.017) and the percentage of seizure-free in the following three months (P = 0.019). No difference was found in the 50% response rate, the 75% response rate, and the percentage of seizure-free between the first three months and the following three months in the whole group and the two subgroups (P > 0.05). The incidence rate of side effects due to the therapy was 19.40% (13 of 67). The side effects were mainly found in the first three months. It is concluded that OXC is the first-line anti-epileptic drug (AED) for partial seizures, and could be used as the monotherapy and add-on therapy for newly diagnosed patients and patients that failed to tolerate or benefit from other AEDs.

Keywords oxcarbazepine      partial epilepsy     
Corresponding Authors: ZHU Suiqiang,Email:zhusuiqiang@163.com   
Issue Date: 05 June 2009
URL:  
http://academic.hep.com.cn/fmd/EN/10.1007/s11684-009-0025-6     OR     http://academic.hep.com.cn/fmd/EN/Y2009/V3/I2/181
base line seizure frequency/times per month
 median4.8
 range1-150
seizure type (n)
 single partial seizure9
 complex partial seizure22
 general tonic-clonic seizure34
 BECTS2
dosage of OXC/mg
 median491.4
 range150-1200
therapy (n)
 monotherapy for newly diagnosed patients18
 patients that could not tolerate other first-line AEDs8
  rash caused by carbamazpine3
  granulocytopenia caused by carbamazpine2
  dental ulcer caused by carbamazpine1
  hepatic dysfunction1
  score results decrease caused by topamax1
 add-on therapy for partial epilepsy patients17
 monotherapy when other AEDs were ineffective24
 (including traditional medicine)
results of imageology diagnosis (n)
 normal36
 temporal lobe lesion8
 occipital lobe lesion4
 parietal lobe lesion4
 undone15
results of EEG tests (n)
 normal17
 abnormal background9
 epileptic discharge41
  widespread9
  focal32
past history and personal history (n)
 febrile seizure11
 cerebral trauma12
 history of peripartum5
 encephalitis4
 intracranial space-occupying lesion3
 developmental malformation1
 family history3
 negative28
Tab.1  The clinical data of the patients in the whole group
OXC monotherapy groupOXC add-on groupwhole group
(n = 52)(n = 15)(n = 67)
the first 3 monthsthe following 3 monthsthe first 3 monthsthe following 3 monthsthe first 3 monthsthe following 3 months
the medium reduction of seizure frequency75.93%78.53%66.52%61.67%71.39%75.41%
50% response rate75.00% (39)76.92% (40)*60.00% (9)46.67% (7)71.64% (48)70.15% (47)
75% response rate69.23% (36)63.46% (33)46.67% (7)33.33% (5)64.18% (43)56.72% (38)
seizure free59.62% (31)*59.62% (31)*26.67% (4)20% (3)52.24% (35)49.25% (33)
Tab.2  Comparison of monotherapy and add-on therapy for partial epilepsy
Fig.1  Comparison of the seizure frequency between the first 3 months and the following 3 months in OXC monotherapy group (a); in OXC add-on therapy group (b); in the whole group (c) ( > 0.05).
groupsthe first 3 monthsthe following 3 months
monotherapy group17.31% (9/52)0
add-on therapy group26.67% (4/15)6.67% (1/15)
Tab.3  The side effects of OXC during the follow-up and the comparison between the first 3 months and the following 3 months
1 Giustizieri M, Armogida M, Berretta N, Federici M, Piccirilli S, Mercuri N B, Nistico R. Differential effect of carbamazepine and oxcarbazepine on excitatory synaptic transmission in rat hippocampus. Synapse , 2008, 62(10): 783-789
doi: 10.1002/syn.20556
2 Ambrosio A F, Soares-Da-Silva P, Carvalho C M, Carvalho A P. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem Res , 2002, 27(1): 121-130
doi: 10.1023/A:1014814924965
3 Dogan E A, Usta B E, Bilgen R, Senol Y, Aktekin B. Efficacy, tolerability, and side effects of oxcarbazepine monotherapy: a prospective study in adult and elderly patients with newly diagnosed partial epilepsy. Epilepsy Behav , 2008, 13(1): 156-161
doi: 10.1016/j.yebeh.2008.02.001
4 Gazzola D M, Balcer L J, French J A. Seizure-free outcome in randomized add-on trials of the new antiepileptic drugs. Epilepsia , 2007, 48(7): 1303-1307
doi: 10.1111/j.1528-1167.2007.01136.x
5 Marson A G, Appleton R, Baker G A, Chadwick D W, Doughty J, Eaton B, Gamble C, Jacoby A, Shackley P, Smith D F, Tudur-Smith C, Vanoli A, Williamson P R. A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial. Health Technol Assess , 2007, 11(37): iii-iv, ix-x, 1-134
6 Herranz J L, Argumosa A, Salas-Puig J. Oxcarbazepine in monotherapy in 324 patients with partial seizures (TRINOVA study). Rev Neurol , 2004, 39(7): 601-606
7 French J A, Kanner A M, Bautista J, Abou-Khalil B, Browne T, Harden C L, Theodore W H, Bazil C, Stern J, Schachter S C, Bergen D, Hirtz D, Montouris G D, Nespeca M, Gidal B, Marks W J Jr, Turk W R, Fischer J H, Bourgeois B, Wilner A, Faught R E Jr, Sachdeo R C, Beydoun A, Glauser T A. Efficacy and tolerability of the new antiepileptic drugs, I: Treatment of new-onset epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia , 2004, 45(5): 401-409
8 French J A, Kanner A M, Bautista J, Abou-Khalil B, Browne T, Harden C L, Theodore W H, Bazil C, Stern J, Schachter S C, Bergen D, Hirtz D, Montouris G D, Nespeca M, Gidal B, Marks W J Jr, Turk W R, Fischer J H, Bourgeois B, Wilner A, Faught R E Jr, Sachdeo R C, Beydoun A, Glauser T A. Efficacy and tolerability of the new antiepileptic drugs, II: Treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia , 2004, 45(5): 410-423
doi: 10.1111/j.0013-9580.2004.06304.x
9 Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, Kalviainen R, Mattson R, Perucca E, Tomson T. ILAE treatment guidelines: Evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia , 2006, 47(7): 1094-1120
doi: 10.1111/j.1528-1167.2006.00585.x
10 Freidel M, Krause E, Kuhn K, Peper R, Vogel H. Oxcarbazepine in the treatment of epilepsy, 2007, 75(2): 100-106
11 Pauletto G, Bergonzi P; Triveneto Epilepsy Study Group. Oxcarbazepine reduces seizure frequency in a high proportion of patients with both newly diagnosed and refractory partial seizures in clinical practice. Seizure , 2006, 15(3): 150-155
doi: 10.1016/j.seizure.2005.12.008
12 Beydoun A, Sachdeo R C, Kutluay E, McCague K, D'Souza J. Sustained efficacy and long-term safety of oxcarbazepine: one-year open-label extension of a study in refractory partial epilepsy. Epilepsia , 2003, 44(9): 1160-1165
doi: 10.1046/j.1528-1157.2003.54102.x
13 Schmidt D, Arroyo S, Baulac M, Dam M, Dulac O, Friis M L, K?lvi?inen R, Kr?mer G, van Parys J, Pedersen B, Sachdeo R. Recommendations on the clinical use of oxcarbazepine in the treatment of epilepsy:a consensus view. Acta Neurol Scand , 2001, 104: 167-170
doi: 10.1034/j.1600-0404.2001.00870.x
14 Schmidt D, Sachdeo R. Oxcarbazepine for treatment of partial epilepsy: A review and recommendations for clinical use. Epilepsy Behav , 2000, 1(6): 396-405
doi: 10.1006/ebeh.2000.0126
15 Freidel M, Krause E, Kuhn K, Peper R, Vogel H. Oxcarbazepine in the treatment of epilepsy. Fortschr Neurol Psychiatr , 2007, 75(2): 100-106
16 Zaccara G, Messori A, Cincotta M, Burchini G. Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies? Acta Neurol Scand , 2006, 114(3): 157-168
doi: 10.1111/j.1600-0404.2006.00705.x
17 Franzoni E, Garone C, Sarajlija J, Gualandi S, Malaspina E, Cecconi I, Moscano F C, Marchiani V. Open prospective study on oxcarbazepine in epilepsy in children: a preliminary report. Seizure , 2006, 15(5): 292-298
doi: 10.1016/j.seizure.2006.02.017
18 Novartis. Oxcarbazepine. Data on file, Basle , 1998
19 Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, Mason A, Golder S, O'Meara S, Sculpher M, Drummond M, Forbes C. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technol Assess , 2005, 9(15): 1-157
20 Aldenkamp A P, De Krom M, Reijs R. Newer antiepileptic drugs and cognitive issues. Epilepsia , 2003, 44(Suppl 4): 21-29
doi: 10.1046/j.1528-1157.44.s4.3.x
21 Beydoun A, Sachdeo R C, Rosenfeld W E, Krauss G L, Sessler N, Mesenbrink P, Kramer L, D'Souza J. Oxcarbazepine monotherapy for partial-onset seizures: a multicenter, double-blind, clinical trial. Neurology , 2000, 54(12): 2245-2251
22 Kraiprab P, Chinvarun Y, Tantisira M H. Oxcarbazepine as add-on therapy in Thai epileptic patients with refractory partial seizures. J Med Assoc Thai , 2005, 88(Suppl 3): S193-201
23 Patsalos P N, Berry D J, Bourgeois B F, Cloyd J C, Glauser T A, Johannessen S I, Leppik I E, Tomson T, Perucca E. Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia , 2008, 49(7): 1239-1276
doi: 10.1111/j.1528-1167.2008.01561.x
No related articles found!
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed